---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000050"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:06:33.449737+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M

## Summary
- Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.
- Cash and investments $111.8M, down from $115.1M at Dec 31, 2024; runway beyond 2026.
- Restructuring & impairment charges $16.1M vs $4.3M YoY; R&D $5.4M, G&A $9.1M.
- AXN-2510/IMM2510 China trial ongoing; initial 1L NSCLC data expected 2H 2025.
- U.S. clinical study of AXN-2510/IMM2510 in 1L NSCLC anticipated before end 2025.

## SEC filing metadata
- accession: 0001789769-25-000050
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/0001789769-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/til-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000050
- JSON: https://secwatch.observer/filing/0001789769-25-000050.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.